title: Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes.
abstract: OBJECTIVE
  A variation of the response to Sodium glucose co-transporter 2 (SGLT2) inhibitors with age has not been investigated in patients with diabetes. The aim of this study was to assess renal threshold of glucose (RTg) before and after administration of an SGLT2 inhibitor in young adult patients (≤40 years) and older adult patients (>40 years) with type 2 diabetes (T2DM).
  
  
  METHODS
  Twenty Japanese patients with T2DM were enrolled. Baseline data were obtained on the first day and dapagliflozin (5 mg) was administered at 6:00 on the second day. Glucose excursions were assessed by continuous glucose monitoring and urine samples were collected every hour during the daytime (7:00 to 15:00) on both days. RTg was estimated from the regression line of the scatter plot of the hourly mean glucose concentrations.
  
  
  RESULTS
  After a single dose of dapagliflozin, RTg decreased from 121.5 to 6.1 mg/dl in the young adult group and from 151.0 mg/dl to -15.8 mg/dl in the older group. After dapagliflozin, the slope of the regression line was significantly steeper in the young adult group.
  
  
  CONCLUSIONS
  Dapagliflozin was more effective in young patients because they showed a larger response of urinary glucose excretion.
authors.affiliation: a Division of Metabolism and Endocrinology, Department of Internal Medicine , St. Marianna University School of Medicine , 2-16-1, Sugao, Miyamae-ku, Kawasaki , Kanagawa 216-8511 , Japan.
authors.forename: Yuta
authors.initials: Y
authors.lastname: Nakamura
authors.affiliation: a Division of Metabolism and Endocrinology, Department of Internal Medicine , St. Marianna University School of Medicine , 2-16-1, Sugao, Miyamae-ku, Kawasaki , Kanagawa 216-8511 , Japan.
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Nagai
authors.affiliation: a Division of Metabolism and Endocrinology, Department of Internal Medicine , St. Marianna University School of Medicine , 2-16-1, Sugao, Miyamae-ku, Kawasaki , Kanagawa 216-8511 , Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Terashima
authors.affiliation: a Division of Metabolism and Endocrinology, Department of Internal Medicine , St. Marianna University School of Medicine , 2-16-1, Sugao, Miyamae-ku, Kawasaki , Kanagawa 216-8511 , Japan.
authors.forename: Ami
authors.initials: A
authors.lastname: Nishine
authors.affiliation: a Division of Metabolism and Endocrinology, Department of Internal Medicine , St. Marianna University School of Medicine , 2-16-1, Sugao, Miyamae-ku, Kawasaki , Kanagawa 216-8511 , Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ishii
authors.affiliation: a Division of Metabolism and Endocrinology, Department of Internal Medicine , St. Marianna University School of Medicine , 2-16-1, Sugao, Miyamae-ku, Kawasaki , Kanagawa 216-8511 , Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kato
authors.affiliation: a Division of Metabolism and Endocrinology, Department of Internal Medicine , St. Marianna University School of Medicine , 2-16-1, Sugao, Miyamae-ku, Kawasaki , Kanagawa 216-8511 , Japan.
authors.forename: Akio
authors.initials: A
authors.lastname: Ohta
authors.affiliation: a Division of Metabolism and Endocrinology, Department of Internal Medicine , St. Marianna University School of Medicine , 2-16-1, Sugao, Miyamae-ku, Kawasaki , Kanagawa 216-8511 , Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Tanaka
mesh_terms: D000328:Adult; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D005260:Female; D005947:Glucose / Q000378:metabolism; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C529054:dapagliflozin; D005947:Glucose
keywords: SGLT2 inhibitor; continuous glucose monitoring; dapagliflozin; renal threshold of glucose; type 2 diabetes